


## Thalidomide-O-amido-PEG4-azide

<b>Cat. No.:</b>	HY-141011		
<b>CAS No.:</b>	2411681-89-3		
<b>Molecular Formula:</b>	C <sub>25</sub> H <sub>32</sub> N <sub>6</sub> O <sub>10</sub>		
<b>Molecular Weight:</b>	576.56		
<b>Target:</b>	PROTAC Linkers		
<b>Pathway:</b>	PROTAC		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### BIOLOGICAL ACTIVITY

<b>Description</b>	Thalidomide-O-amido-PEG4-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs <sup>[1]</sup> . Thalidomide-O-amido-PEG4-azide is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAC) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.
<b>IC<sub>50</sub> &amp; Target</b>	PEGs
<b>In Vitro</b>	PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA